Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC (NCT04448886)
Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)
🩺 Plain-English Summary (8th-Grade Level)
This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: * Sacituzumab govitecan (IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)
Who can join: Review the eligibility criteria below.
Location: Emory University/Winship Cancer Institute — Atlanta, Georgia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Emory University/Winship Cancer Institute — Atlanta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- Dana Farber Cancer Institute — Boston, Massachusetts
- DFCI @ Foxborough — Foxborough, Massachusetts
- DFCI @ Milford Regional Hospital — Milford, Massachusetts
- DF/BWCC in Clinical Affiliation with South Shore Hospital — South Weymouth, Massachusetts
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- University of Pennsylvania-Abramson Cancer Center — Philadelphia, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Invasive Breast Cancer
- Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions — Cleveland, Ohio
- Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer — Milwaukee, Wisconsin
- Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer — New York, New York
- TRUDI: TDXD+Durva in HER2+/Low IBC — Boston, Massachusetts
- Sacituzumab Govitecan In TNBC — Boston, Massachusetts
Explore by condition: All Invasive Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.